期刊文献+

阿苯达唑纳米微粉分散方法的研究 被引量:1

Study on Dispersion Method of Albendazole Nanometer Powder
原文传递
导出
摘要 目的:建立适于生物安全性研究的阿苯达唑(ABZ)纳米微粉的最佳分散方法。方法:选择超纯水、RPMI 1640完全培养基、RPMI 1640培养液、磷酸盐缓冲液(PBS)、0.9%氯化钠溶液5种分散介质,在扫描电镜下观察ABZ纳米微粉粒子的分散形态,并检测其粒径,与基础值比较来确定分散介质;之后以普通超声、先普通超声再细胞破碎超声两种分散方式分别分散ABZ纳米微粉,以粒径为考察指标,与基础值比较筛选最佳分散方法;并在此基础上考察普通超声时间为5~60 min时的粒径变化趋势,以确定超声时间。结果:ABZ纳米微粉在5种分散介质中均发生了不同程度的聚合,与基础值比较粒径也普遍变大,但在PBS、0.9%氯化钠溶液和超纯水中聚合程度相对轻微,粒径增大幅度也较小,结合细胞对生长环境的特殊要求选择分散介质为PBS。采用先普通超声再细胞破碎超声的分散方式,ABZ纳米微粉粒径未见显著增大。超声5~45 min,随着超声时间的延长ABZ纳米微粉的粒径不断减小;超声45~60 min,随着超声时间的的延长ABZ纳米微粉的粒径反而有团聚增大的趋势,综合时间成本选择超声时间为30 min。验证试验ABZ纳米微粉的平均粒径为(387±3.6)nm,与基础值比较差异无统计学意义(P〉0.05)。结论:本分散方法可有效抑制纳米微粉悬浮液的团聚,适用于ABZ纳米微粉的生物安全性研究。 OBJECTIVE: To establish the optimal dispersion method of Albendazole (ABZ) nanometer powder for biological safety study. METHODS: Using ultrapure water, RMPI 1640 complete medium, RMPI 1640 culture medium, phosphate buffer (PBS) and 0.9% sodium chloride as medium, the morphology and particle size of ABZ nanometer powder were observed under SEM and compared with baseline to confirm the dispersion medium. ABZ nanometer powder was dispersed by conventional ultra- sound or clasmatosis ultrasound following conventional ultrasound, respectively. The particle size of ABZ nanometer powder was in- vestigated and then compared with baseline to screen the optimal dispersion method. The change of particle size was investigated un- der 5-60 min of conventional ultrasound to confirm the duration of ultrasound. RESULTS : The different degree of polymerization of ABZ nanometer powder appeared in 5 kinds of dispersion mediums; the particle size of them were all higher than baseline. The po- lymerization of ABZ nanometer powder was slightly in PBS, 0.9% sodium chloride and ultrapure water, and the increase of parti- cle size was also slightly. PBS was suitable medium for special growth environment of cell. By means of clasmatosis ultrasound fol- lowing conventional ultrasound, the particle size of ABZ nanometer powder was increased slightly. Within 5-45 min, the particle size of ABZ nanometer powder was decreasing with ultrasound time; within 45-60 min, the particle size of ABZ nanometer powder was growing and reuniting with ultrasound time. The ultrasound duration lasted for 30 min based on time cost. Mean particle size of ABZ nanometer powder was (387 ± 3.6) nm; there SIONS: The method can inhibit the polymerization study of ABZ nanometer powder. was no significant difference between it and baseline (P〉0.05). CONCLU- of nanometer powder effectively, and it is suitable for the biological safety
出处 《中国药房》 CAS CSCD 2013年第37期3507-3509,共3页 China Pharmacy
基金 国家科技计划863重点计划资助项目(No.2007AA021805) 新疆医科大学第一附属医院药学专项基金资助项目(No.2011YX01)
关键词 阿苯达唑 纳米微粉 分散方法 分散介质 粒径 生物安全性 Albendazole Nanometer powder Dispersion method Dispersion medium Particle size Biological safety
  • 相关文献

参考文献11

二级参考文献77

  • 1肖树华,尤纪青,焦佩英,郭惠芳,黄立信,柴君杰,焦伟.甲苯达唑、阿苯达唑及其代谢物实验治疗小鼠继发性细粒棘球蚴病的研究[J].地方病通报,1990,5(3):11-16. 被引量:14
  • 2钱帅,张建军,高缘,周建平.纳米混悬剂研究进展[J].药学进展,2007,31(1):9-14. 被引量:16
  • 3陈华,刘亚青.超临界流体快速膨胀法制备微细颗粒[J].化工科技,2006,14(6):44-48. 被引量:1
  • 4Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs [J]. Int J Pharm, 2004, 284 (1-2): 109-122.
  • 5Duchene D, Bochot A, Yu SC, et al. Cyclodextrins and emulsions[J].Int J Pharm, 2003, 266 (1-2) : 85-90.
  • 6Suitthimeathegorn O, Jaitely V, Florence AT. Novel anhydrous emulsions: formulation as controlled release vehicles [J]. Int J Pharm, 2005, 298 (2): 367-371.
  • 7Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future[J]. Adv Drug Deliv Rev, 2001, 47 (1) : 3-19.
  • 8Fakes MG, Vakkalagadda B J, Qian F, et al. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches [J]. Int J Pharm, 2009, 370(1-2): 167-174.
  • 9Moschwitzer J, Achleitner G, Pomper H, et al. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology [J]. Eur J Pharm Biopharm, 2004, 58 (3) : 615-619.
  • 10Pilcer G, Vanderbist F, Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery [J3. Int J Pharm, 2009, 365 (1-2) : 162-169.

共引文献382

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部